Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate
- Conditions
- Rheumatoid Arthritis
- Registration Number
- NCT00069017
- Lead Sponsor
- MedImmune LLC
- Brief Summary
To compare, as a preliminary analysis, the effects of MEDI-522 versus placebo at 6 months on disease activity (ACR20) and progression of structural joint damage.
- Detailed Description
To compare, as a preliminary analysis, the effects of subcutaneously administered MEDI-522 versus placebo at 6 months on disease activity and progression of structural joint damage in patients with rheumatoid arthritis (RA), who have active disease despite ongoing treatment with methotrexate (MTX) with or without hydroxychloroquine (HCQ) and/or sulfasalazine (SSZ).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (40)
The University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Sun Valley Arthritis Center
🇺🇸Glendale, Arizona, United States
Arizona Research & Education
🇺🇸Phoenix, Arizona, United States
University of Arizona
🇺🇸Tucson, Arizona, United States
Fayetteville Diagnostic Clinic, Ltd.
🇺🇸Fayetteville, Arkansas, United States
Thornton Hospital
🇺🇸La Jolla, California, United States
Boling Clinical Trials
🇺🇸Rancho Cucamonga, California, United States
Pacific Arthritis Center Medical Group
🇺🇸Santa Maria, California, United States
Arthritis and Rheumatic Disease Specialty
🇺🇸Aventura, Florida, United States
Centre for Rheumatology, Immunology & Arthritis
🇺🇸Fort Lauderdale, Florida, United States
Scroll for more (30 remaining)The University of Alabama at Birmingham🇺🇸Birmingham, Alabama, United States